Bibliographic Production

Peer-Reviewed  Journals:

  1. S.Y. Oh, A. Amalfitano, K. Frederici, M.C. Chen, and M.M. Fluck.  Low probability of double integration in transformation of nonpermissive cells by polyomavirus.  J. of Virology, Vol. 62., p. 1304-1313, 1990.
  2. J.A. Wirth, A. Amalfitano, R. Gross, M.B.A. Oldstone, and M.M. Fluck.Organ and age specific replication of polyomavirus in mice.  J. of Virology. Vol. 66, p. 3278-3286, 1992.
  3. A. Amalfitano, L.G. Martin, and M.M. Fluck.  Different roles for two enhancer domains in the organ and age specific pattern of polyomavirus replication in the mouse.  Molecular and Cellular Biology, Vol. 12, p. 3628-3635, 1992.
  4. A. Amalfitano and J.S. Chamberlain.  The mdx-ARMS assay- A simple and rapid PCR based detection of the mdx allele.  Muscle and Nerve 19: pp. 1549-1553, 1996.
  5. A. Amalfitano, C.A. Begy, and J.S. Chamberlain.  Improved adenovirus packaging cell lines to support the growth of replication defective gene delivery vectors.  Proc. Natl. Acad. Sci. Vol. 93 (8) pp. 3552-3556, 1996.
  6. A. Amalfitano and J.S. Chamberlain. Isolation and characterization of 293 cells which coexpress the Ad-pol and pTP proteins- Implications for gene therapy.  Gene Therapy 4 (3) pp. 258-263, 1997.
  7. M.A. Hauser, A. Amalfitano, R. Kumar-Singh, S. Hauschka, and J.S. Chamberlain.  Improved adenoviral vectors for gene therapy of muscular dystrophy.  Neuromuscular Disorders (7) p 277-283, 1997.
  8. A. Amalfitano, M. A. Hauser, H. Hu, D. Serra, C. R. Begy, and J. S. Chamberlain. Production and characterization of improved adenovirus vectors deleted for the E1, E2b, and E3 genes.   J. Virology, 72(2), pp. 926-933, 1998.
  9. Dubowitz syndrome:  A defect in the cholesterol biosynthetic pathway?.  A. Ahmad, A. Amalfitano, Y.T. Chen, and P. Kishnani. Amer. J. Med. Genetics (86) p.503-504. 1999.
  10. H. Hu., D. Serra, and A. Amalfitano. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice.  Human Gene Therapy 10 (3) p354-363, 1999.
  11. A. Amalfitano, A. J. McVie-Wylie, H. Hu, T.L. Dawson, N. Raben, . Plotz, and Y.T. Chen. Systemic correction of the muscle disorder glycogen storage disease-Type II after hepatic targeting of a modified adenovirus vector encoding human acid-a-glucosidase.  Proc. Natl. Acad. Sci (USA) Vol 96 (16) p8861-8866, 1999.
  12. D. Hartigan-O’Connor, A. Amalfitano. and J.S. Chamberlain. Improved production of gutted adenovirus in cells expressing preterminal protein and DNA polymerase.  J. Virology. 73 (9) p. 7835-7841,1999
  13. A. Amalfitano. Next Generation Adenoviral Vectors: New and Improved.  Gene Therapy, (6) 1643-1645, Oct. 1999.
  14. Y.T.  Chen and A. Amalfitano.  Towards a molecular therapy for glycogen storage disease type-II (Pompe disease).  Molecular Medicine Today, (6)245-251, 2000.
  15. B.L. Hodges, D. Serra, H. Hu,  C.R. Begy, J. S. Chamberlain, and A. Amalfitano. Multiply Deleted [E1-, polymerase-, pTP-] Adenovirus Vector persists despite deletion of the preterminal protein.   J.Gene Medicine (2)250-259, 2000.
  16. A. Ahmad, M. Brinson, B. Hodges, J.S. Chamberlain, and A. Amalfitano. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for DMD. Human Molecular Genetics. Vol. 9, No. 17 2507-2515 2000.
  17. A.Amalfitano, R. Bengur, R. P. Morse, J. M. Majure, L. E. Case, D. L. Veerling., J. Mackey, P. Kishnani, W. Smith, A. McVie-Wylie, J. A. Sullivan, G. E. Hoganson, J.  A. Phillips, G.B. Schaefer, J. Charrow, R.E.Ware, E.H.Bossen, Y.T. Chen.  Recombinant human acid-alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phaseI/II clinical trial. Genetics in Medicine. Volume 3, (2), 132-138:2001. 
  18. A.E. Luebke, J.D. Steiger, B.L. Hodges, and A. Amalfitano. A modified adenovirus can transfect cochlear hair cells in vivo without compromising cochlear function. Gene Therapy, 8(10):789-794, 2001.
  19. B.L. Hodges, H. K. Evans, R. Everett, E.Y. Ding, D. Serra, and A. Amalfitano.   Adenovirus vectors deleted for the 100K gene, and their potential for multiple gene therapy applications.  J. Virology, 75(18): pp. 5913-5920:2001.
  20. E. Ding, B.L. Hodges, H. Hu, A.J. McVie-Wylie, D. Serra, F. Migone, D. Pressley, Y.T. Chen, and A. Amalfitano.  Long term efficacy after [E1-,E2b-] adenovirus mediated hepatic transfer of the human acid-a-glucosidase gene into GSD-II knockout mice. Human Gene Therapy, 12(8) pp 955-966: 2001.
  21. R. Gilbert, J. Nalbantoglu, J. McC. Howell, L. Davies, S. Fletcher, A. Amalfitano, B. J. Petrof, A. Kamen, B. Massie, and G. Karpati.    Dystrophin expression in muscle following gene transfer with a fully deleted (Gutted) adenovirus is markedly improved by trans-acting adenoviral gene products". Human Gene Therapy.12(14) pp: 1741-1755:2001
  22. N. Rylova, A. Amalfitano, D.A. Sawin-Persaud, W. X. Guo, J. Chang, P. J. Jansen, A. D. Proia, and R. Boustany. The CLN3 Gene is a Novel Molecular Target for Cancer Drug Discovery.  SCancer Research. 62(3) pp:801-808:2002.
  23. J. D. Harris, I. R. Graham, S. Schepelmann, A. K. Stannard, M. L. Roberts, B. L. Hodges, Vanessa Hill, A. Amalfitano, D. G. Hassall, J. S. Owen, G. Dickson. Acute regression of advanced. and retardation of early, aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of second generation [E1¯, E3¯, polymerase¯] adenovirus vector expressing human apoE. Human Molecular Genetics 11(1) pp:43-58: 2002.
  24. S. Dhar, R. L. Bitting, S. N. Rylova, P. J. Jansen, E. Lockhart, D. D. Koeberl, A. Amalfitano, and R.N. Boustany. Flupirtine blocks apoptosis in Batten patient lymphoblasts and in human post-mitotic CLN3 and CLN2 deficient neurons. Annals of Neurology:Annals of Neurology (51) pp: 448-466: 2002.
  25. E.Y.Ding, H.Hu, B.L. Hodges, F. Migone, D. Serra, F. Xu, Y.T. Chen, A. Amalfitano. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent upon vector dose, transgene promoter, and the tissues targeted for vector  transduction.  Molecular Therapy Vol 5 (4) pp: 436-446:2002.
  26. A. Amalfitano, R. J. Parks. Separating Fact from Fiction: Assessing the potential of modified Adenovirus vectors for use in Human Gene Therapy.  . Current Gene Therapy Volume 2: pp 111-133: 2002.
  27. Sun BD, Chen Y-T, Bird A, Amalfitano A, and Koeberl DD.  Long-term correction of glycogen storage disease type II with a hybrid adenovirus-adeno-associated virus vector.  Molecular Therapy Vol 7 (2): pp: 193-201:2003.
  28. Dode C. Levilliers J. Dupont JM. De Paepe A. Le Du N. Soussi-Yanicostas N. Coimbra RS. Delmaghani S. Compain-Nouaille S. Baverel F. Pecheux C.Le Tessier D. Cruaud C. Delpech M. Speleman F. Vermeulen S. Amalfitano A. Bachelot Y. Bouchard P. Cabrol S. Carel JC. Delemarre-van de Waal H.Goulet-Salmon B. Kottler ML. Richard O. Sanchez-Franco F. Saura R. Young J. Petit C. Hardelin JP. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nature Genetics. 33(4):463-465, 2003.
  29. A. Amalfitano. Use of multiply deleted Adenovirus vectors to probe Adenovirus vector performance and toxicities.  Current Opinion in Molecular Therapeutics Vol.5(4): 362-366, 2003.
  30. A.J. McVie-Wylie, E.Y. Ding, T. Lawson, D. Serra, F.K. Migone, D. Pressley,  M. Mizutani, T. Kikuchi, Y.T. Chen, and A. Amalfitano. Multiple muscles in the AMD quail can be “cross-corrected” of pathologic glycogen accumulation after intravenous injection of an [E1-,polymerase-] adenovirus vector encoding human acid-α-glucosidase.:  J. Gene Medicine:Vol 5: 399-406, 2003.
  31. Sun BD, Chen Y-T, Bird A, Xu F, Hou Y-X, Amalfitano A, and Koeberl DD.  Packaging of an AAV vector encoding human acid α-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector.  Mol Therapy Vol.7 (4):467-477, 2003.
  32. Everett, RS.  B.L. Hodges, E.Y. Ding, F. Xu,  D. Serra, and  A. Amalfitano .  Liver toxicities typically induced by first generation Adenovirus vectors can be reduced with use of [E1-, E2b-] adenoviral vectors.   Human Gene Therapy Vol.14: 1715-1726. 2003.
  33. Hunley,TE.,  D. Corzo, M. Dudek, P. Kishnani, A. Amalfitano, Y.T. Chen, S.M. Richards, J.A. Phillips III, A.B. Fogo, G. E.Tiller. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.  Pediatrics :114: e532-e535: 2004.
  34. R.S. Everett, H.K. Evans, B. Hodges, E.Y. Ding, D. Serra, and A. Amalfitano.  Strain specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1-, E2b-] Adenoviral vectors.  Virology.  Vol. 325:96-105. 2004.
  35. F. Xu, E. Ding, S. Liao, F. Migone, A. Schneider, D. Serra, Y. Chen, A. Amalfitano. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune deficient GSD-II mouse model.Gene Therapy. Vol. 11: 1590-1598:2004.
  36. Jiang H. Wang Z. Serra D. Frank MM. Amalfitano A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-Ad antibodies. Molecular Therapy: the Journal of the American Society of Gene Therapy. 10(6):1140-2, 2004 Dec.
  37. David P. Corey, Jaime García-Añoveros, Jeffrey R. Holt, Kelvin Y. Kwan, Shuh-Yow Lin, Melissa A. Vollrath, Andrea Amalfitano, Eunice L.-M. Cheung, Bruce H. Derfler, Anne Duggan, Gwénaëlle S. G. Géléoc, Paul A. Gray, Matthew P. Hoffman, Heidi L. Rehm, Daniel Tamasauskas, Duan-Sun Zhang.  TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells.  Nature: 432(7018):pp723-730.2004
  38. F. Xu, E. Ding, F. Migone, A. Schneider, D. Serra, Y. Chen, A. Amalfitano.  Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intra-venous injection with a modified adenoviral vector expressing hGAA.  J. Gene Medicine.7(2):171-178.2005
  39. Baodong Sun, Haoyue Zhang, Luis M. Franco, Sarah P. Young, Ayn Schneider, Andrew Bird, Andrea Amalfitano, Y.-T. Chen, and Dwight D. Koeberl.  Efficacy of an Adeno-Associated Virus 8 Pseudotyped (AAV2/8) Vector in Glycogen Storage Disease Type II (GSD-II).Molecular Therapy 2005 11(1):57-65.2005
  40. Peppel K, Zhang L, Orman ES, Hagen PO, Amalfitano A, Brian L, Freedman NJ.  Activation of vascular smooth muscle cells by TNF and PDGF: overlapping and complementary signal transduction mechanisms. Cardiovasc Res.65(3):674-82.2005
  41. Yan An,Priya S. Kishnani; David S.  Millington;;Andrea Amalfitano;Deyanira  Corzo; Y.T. Chen.  Glucose Tetrasaccharide as a Biomarker for Monitoring the Therapeutic Response to Enzyme Replacement Therapy for Pompe Disease.  Mol Gene.t Metab. 85(4):247-54.2005.
  42. Franco LM, Sun B. Yang X, Bird A, Zhang H, Schneider A, Brown T, Young SP, Clay TM, Amalfitano A., Chen YT, Koeberl DD.  Evasion of Immune Responses to introduced human acid alpha glucosidase by liver restricted expression in glycogen storage disease Type II. Mol Therapy 12(5):876-84.2005.
  43. Kiang A, Hartman ZC, Liao S., Xu F, Serra D. Palmer D., Ng P., Amalfitano A.  Fully deleted adenovirus persistently expressing GAA accomplishes long term skeletal muscle glycogen correction in tolerant and non-tolerant GSD-II mice. .Mol Therapy, 13(1):127-34, 2006.
  44. Julian D. Harris, Ian R. Graham,  Andrea Amalfitano, James S. Owen, George Dickson.  Delivery of human apoE to liver by an [E1-,E3-,polymerase-,pTP-] adenovirus vector containing a liver specific promoter inhibits atherogenesis in immunocompetent apoE-deficient mice.  Gene Therapy and Molecular Biology. (10)  pp:17-30:2006.
  45. Kishnani,P.S.; Nicolino,M.; Voit,T.; Rogers,R.C.; Tsai,A.C.; Waterson,J.; Herman,G.E.; Amalfitano,A.; Thurberg,B.L.; Richards,S.; Davison,M.; Corzo,D.; Chen,Y.T.; Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. Journal of Pediatrics 149(1)p89-97.2006
  46. Li H. Li JZ. Pittman DD. Amalfitano A. Hankins GR. Helm GA. Comparison of osteogenic potentials of human rat BMP4 and BMP6 gene therapy using [E1-] and [E1-,E2b-] adenoviral vectors. International Journal of Medical Sciences. 3(3):97-105, 2006.
  47. A. Kiang, Z. Hartman, R. Everett, D. Serra, H. Jiang, M. M. Frank, A. Amalfitano.  Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.  Molecular Therapy.14(4):588-598.2006
  48. Barry W McColl, PhD, Ailsa McGregor, PhD, Andrew Wong, BSc, Julian Harris, MPhil,Andrea  Amalfitano, Sandra Magnoni, Andrew Baker,  George Dickson, Karen Horsburgh. APOE e3 gene transfer attenuates brain damage after experimental stroke.  Journal of Cerebral Blood Flow and Metabolism. J. Cereb Blood Flow Metab. 27(3):477-87: 2007.
  49. Zachary C. Hartman, Esther P. Black, Andrea Amalfitano.  Adenoviral Infection Induces a Multi-Faceted Innate Cellular Immune Response that is mediated by the Toll-Like Receptor pathway in A549 cells.Virology. 358(2): 357-72:2007.
  50. Zachary C. Hartman, Anne Kiang, Ruth S. Everett, Delila Serra, Xiao Y. Yang, Timothy M. Clay, Andrea Amalfitano.  Adenovirus infection triggers a rapid, MyD88 regulated, transcriptome response critical to acute phase and adaptive immune responses in vivo. J. Virology. 81(4): 1796-1812: 2007.
  51. Scott E. Hensley and Andrea Amalfitano. Toll-like receptors impact on safety and efficacy of gene transfer vectors. Molecular Therapy 15 (8): p1417-1422. 2007.
  52. A. Kiang and A. Amalfitano. Progress and Problems when considering gene therapy for GSD-II. ACTA Myologica Jul;26(1):49-52. 2007
  53. Zachary C. Hartman, Daniel M. Appledorn, Andrea Amalfitano. Adenovirus vector induced Innate Immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Research:132(1-2)pp1-14.2008.
  54. Zachary C. Hartman, Daniel M. Appledorn, Delila Serra, Oliver Glass, Todd Mendelson, Timothy Clay, and Andrea Amalfitano. Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology. 2008 May 10;374(2):453-67. Epub 2008 Feb 15.
  55. Daniel M. Appledorn, Anne Kiang, Aaron McBride, Haixiang Jiang, Sergey Seregin, Jeannine M. Scott, Ryan Stringer, Youssef Koussa, Meghan Hoban, Michael M. Frank, Andrea Amalfitano. Wild-type Adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Therapy. (12):885-901.2008.
  56. Daniel M. Appledorn, Patial, S., McBride, A., Godbehere, S., Van Rooijen, N., Parameswaran, N., Andrea Amalfitano.  Adenovirus vector induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol.;181(3):2134-44. 2008.
  57. Daniel M. Appledorn, McBride, A., Seregin S., Scott, J.M., Schuldt, N., Kiang, A., Godbehere, S., Andrea Amalfitano.Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Therapy. 15 (24):1606-1617. 2008.
  58. Katherine J. Motyl, Sergiu Botolin, Regina Irwin, Daniel M. Appledorn, Tejas Kadakia, Andrea Amalfitano, Richard C. Schwartz, Laura R. McCabe.  Bone Inflammation and Altered Gene Expression with Type I Diabetes Onset. Journal of Cellular Physiology, 2009 Mar;218(3):575-83.PMID: 19006181.
  59. Takuya Osada, Christopher Y. Woo, Matthew McKinney, Xiao Yi Yang, Gangjun Lei, Heather G. LaBreche, Zachary C. Hartman, Donna Niedzweicki, Nelson Chao, Andrea Amalfitano,  Michael A. Morse, H. Kim Lyerly, and Timothy M. Clay.  Induction of Wilms’ tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.  Clinical Cancer Research, 2009 Apr 15;15(8):2789-96. Epub 2009 Apr 7.PMID: 19351755 .
  60. Elizabeth S. Gabitzsch,Younong Xu, Lois H. Yoshida, Joseph Balint, Nordin Zeidner, Richard B. Gayle,  Andrea Amalfitano, Frank R. Jones.  A Preliminary and Comparative Evaluation of a Novel Ad5 [E1-, E2b-] Recombinant Based Vaccine Used to Induce Cell Mediated Immune Responses. Immunology Letters,2009 Jan 29;122(1):44-51. Epub 2008 Dec 13.PMID: 19073216 .
  61. Sergey S. Seregin, Daniel M. Appledorn, McBride, A.J., Schuldt, N., Aldhamen, YA., Voss, T., Junping, Wei, Bujold, M., Nance, W., Godbehere, S., and Andrea Amalfitano. Transient pre-treatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Molecular Therapy, 2009 Apr;17(4):685-96. Epub 2009 Jan 27.PMID: 19174760.
  62. Vijay A.K. Rathinam, Daniel M. Appledorn, Kathleen A. Hoag, Andrea Amalfitano, Linda S. Mansfield: Campylobacter jejuni-induced activation of dendritic cells involves cooperative signaling through TLR4-MyD88 and TLR4-TRIF axes. Infection and Immunity: 2009 Jun;77(6):2499-507. Epub 2009 Mar 30.PMID: 19229288.
  63. Daniel M. Appledorn, Patial, S., Godbehere, S., Parameswaran, N., and Andrea Amalfitano.  TRIF, and TRIF interacting TLRs, differentially modulate several Ad vector induced immune responses. Journal of Innate Immunity; 2009: 1:376–388.
  64. Takuya Osada, Xiao Yi Yang, Zachary Hartman, Oliver Glass, Bradley L. Hodges, Donna Niedzwiecki, Michael A. Morse, H. Kim Lyerly, Andrea Amalfitano (Corresponding Author) & Timothy M. Clay.  Optimizing vaccine responses with an E1, E2b, and E3 deleted adenovirus serotype 5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Therapy: 16:673-682.2009
  65. Sergey S. Seregin, Yasser A. Aldhamen, Daniel M. Appledorn, Nathaniel J. Schuldt, Aaron J. McBride, Mathew Bujold, Sarah S. Godbehere, and Andrea Amalfitano.  CR1/2 is an important suppressor of Adenovirus induced innate immune responses and is required for induction of neutralizing antibodies.  Gene Therapy, 16 (10), 1245–1259; 2009. Epub 2009 Jun 25.PMID: 19554032
  66. E.S. Gabitzsch, Y. Yu, L.H. Yoshida, J. Balint, A. Amalfitano, and F.R. Jones.  Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine: 2009 Oct 30;27(46):6394-8. Epub 2009 Jun 24.PMID: 19559110
  67. Sergey S. Seregin, Daniel M. Appledorn, Patial, S., Bujold, M, Nance, W., Godbehere, S., Narayanan Parameswaran, and Andrea Amalfitano.  β-Arrestins modulate Adenovirus vector induced innate immune responses: differential regulation by β-arrestin-1 and β-arrestin-2. Virus Research: 2010 Jan;147(1):123-34. Epub 2009 Nov 6.PMID: 19896992
  68. Sergey S. Seregin and Andrea Amalfitano.  Overcoming pre-existing Adenovirus immunity by genetic engineering of Adenovirus based vectors.  Expert Opinion on Biological Therapy. 2009 Dec;9(12):1521-31. PMID: 19780714
  69. Daniel M. Appledorn, Yasser Ali Aldhamen, William DePas, Sergey S. Seregin, Chyong-Jy Joyce Liu, Nathan Schuldt, Darin Quach, Dionisia Quiroga, Sarah Godbehere, Igor Zlatkin, Sungjin Kim, J. Justin McCormick, Andrea Amalfitano. A novel Adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to antigenic  targets.2010: PLoS ONE 5(3): e9579.PMID:20221448
  70. Michael A. Morse, Junping Wei, Zachary Hartman, Wenle Xia, Xiu-Rong Ren, Gangjun Lei6, William Barry, Takuya Osada8, Amy Hobeika, Sharon Peplinski, Haixiang Jiang, Gayathri R. Devi, Wei Chen, Neil Spector, Andrea Amalfitano, H. Kim Lyerly, & Timothy M. Clay. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.  International Journal of Cancer.  2010 Jun 15;126(12):2893-903.PMID: 19856307
  71. Seregin, S.S., Z.C. Hartman, D.M. Appledorn, S. Godbehere, H. Jiang, M.M. Frank, and A. Amalfitano. 2009. Novel Adenovirus vectors “capsid-displaying” a human complement inhibitor. J Innate Immun. 2010;2(4):353-9. Epub 2010 Feb 11.PMID: 20375551
  72. Hartman ZC, Wei J, Osada T, Glass O, Lei G, Yang XY, Peplinski S, Kim DW, Xia W, Spector N, Marks J, Barry W, Hobeika A, Devi G, Amalfitano A, Morse MA, Lyerly HK, Clay TM.  An Adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicity and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Res. 2010 Mar 1;16(5):1466-77. Epub 2010 Feb 23.PMID: 20179231
  73. S. S. Seregin, Y. A. Aldhamen, D. M. Appledorn, Z. C. Hartman, N. J. Schuldt, J. Scott, S. Godbehere, H. Jiang, M. M. Frank, and A. Amalfitano. Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad-vector triggered immune responses in vitro and in vivo. Blood. 2010 116(10) pp.1669-1677. [Epub ahead of print]PMID: 20511542.
  74. Porter KJ, Gonipeta B, Parvataneni S, Appledorn DM, Patial S, Sharma D, Gangur V, Amalfitano A, Parameswaran N.  Regulation of lipopolysaccharide-induced inflammatory response and endotoxemia by beta-arrestins.  J Cell Physiol. 2010 Jun 29. [Epub ahead of print]  PMID: 20589830
  75. Sonika Patial, Yogesh Saini, Sitaram Parvataneni, Daniel M. Appledorn, Gerald W. Dorn II,John J. LaPres, Andrea Amalfitano,  Patricia Senagore, Narayanan Parameswaran.  Myeloid-specific GPCR kinase-2 negatively regulates NFĸB1p105-ERK pathway and limits endotoxemic shock in mice. Journal of Cellular Physiology. 226(3):627-637.2011 PMID: 20717897
  76. Daniel M. Appledorn, Yasser A. Aldhamen, Sarah Godbehere,Sergey S. Seregin, Andrea Amalfitano.  Sublingual administration of an Adenovirus based vaccine confirms TLR agonist activity in the oral cavity and elicits improved mucosal and systemic cell mediated responses against HIV antigens despite  pre-existing Ad5 immunity.  Clinical and Vaccine Immunology, 2011 Jan;18(1):150-60. Epub 2010 Nov 17.PMID:21084461.
  77. Yasser A.  Aldhamen, Daniel M.  Appledorn, Sergey S.  Seregin, Chyong-jy J. Liu, Nathaniel J Schuldt, Sarah Godbehere, Andrea Amalfitano.  Expression of the SLAM family of receptors adaptor EAT-2 as a novel strategy for enhancing beneficial immune responses to vaccine antigens. Journal of Immunology, 2011 Jan 15;186(2):722-32. Epub 2010 Dec 13. PMID:21149608
  78. Irini Evnouchidou, Ram Kamal, Sergey S. Seregin, Yoshikuni Goto, Masafumi Tsujimoto, AkiraHattori, Paraskevi V. Voulgari, Alexandros A. Drosos, Andrea Amalfitano, Ian A. York, and Efstratios Stratikos.  Coding single nucleotide polymorphisms of ERAP1 can affect antigenic peptide generation in vitro by influencing basic enzymatic properties of the enzyme. Journal of Immunology, 2011 Feb 15;186(4):1909-13. Epub 2011 Jan 17 PMID:21242517
  79. Seregin S.S., Yasser A. Aldhamen, Daniel M. Appledorn, Jennifer Zehnder, Tyler Voss, Sarah Godbehere  and Andrea Amalfitano.  Use of DAF-displaying Adenovirus vectors reduces induction of transgene and vector specific adaptive immune responses in mice. Human Gene Therapy, 2011 Apr 18. [Epub ahead of print]. PMID:21388344
  80. Sergey S. Seregin, Yasser A. Aldhamen, Daniel M. Appledorn, Charles F. Aylsworth, Sarah Godbehere, Chyong-Jy Joyce Liu, Dionisia Quiroga and Andrea Amalfitano.  TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo. PLoS ONE, 2011;6(7):e22064. Epub 2011 Jul 8. PMID:21760953
  81. Nathaniel J. Schuldt, Yasser A. Aldhamen, Daniel M. Appledorn, Sergey S. Seregin, Youssef Kousa, Sarah Godbehere, Andrea Amalfitano. Vaccine platforms combining Circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses, PLoS ONE , 2011:6(8):e24147 PMID:21912619.
  82. Sergey S. Seregin, Yasser A. Aldhamen, David P.W. Rastall, Sarah Godbehere, and Andrea Amalfitano.  Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.  Vaccine: 2012 Feb 14;30(8):1492-501PMID:22200503.
  83. Seregin S.S, Amalfitano, A.Improving Adenovirus Based Gene Transfer:
    Strategies to Accomplish Immune Evasion. Special Edition on Adenoviral Vectors,  Viruses. Viruses 20102(9), 2013-2036. PMID:21994718
  84. Seregin, S.S., and A. Amalfitano. 2011. Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects. Current Pharmaceutical  Design. 17(24): 2558-74. PMID: 21774776
  85. Amalfitano A, Aldhamen, Y.A., Seregin, S.S. Immune recognition of Gene Transfer Vectors: Focus on Adenovirus as a Paradigm. Frontiers in Microbial Immunology, 2011;2:40. PMID:22566830
  86. Suhrad G Banugaria, Trusha T Patel, Joanne Mackey, Stuti Das, Andrea Amalfitano, Amy S Rosenberg, Joel Charrow, Yuan-Tsong Chen, Priya S Kishnani.  Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody secreting plasma cells. Molecular Genetics and Metabolism. 2012: 105(4):677-80. PMID:22365055
  87. Nathaniel J. Schuldt, Yasser A. Aldhamen, Sarah Godbehere-Roosa, Sergey S. Seregin, Youssef A. Kousa, Andrea Amalfitano.  Immunogenicity when utilizing Adenovirus serotype 4 and 5 vaccines expressing Circumsporozoite protein in naïve and Ad5 immune mice.  Malaria Journal. 2012: (11):209.  PMID:22720732
  88. Yasser Ali Aldhamen, Sergey S. Seregin, Nathaniel J. Schuldt, David P.W. Rastall, Chyong-jy J. Liu, Sarah Godbehere, Andrea Amalfitano. Vaccines Expressing the Innate Immune Modulator EAT-2 Elicit Potent and Durable Effector Memory T Lymphocyte Responses Despite Pre-existing Vaccine Immunity. 2012: Journal of Immunology. 189(3):1349-59. PMID: 22745373.
  89. Nathaniel J. Schuldt and Andrea Amalfitano.  Malaria Vaccines: Focus on Adenovirus based vectors. Vaccine. 2012: 30(35):5191-98. PMID:22683663
  90. Irini Evnouchidou, James Birtley, Sergey Seregin, Athanasios Papakyriakou, Efthalia Zervoudi, Martina Samiotaki, George Panayotou, Petros Giastas, Olivia Petrakis, Dimitris Georgiadis, Andrea Amalfitano, Emmanuel Saridakis, Irene M. Mavridis and Efstratios Stratikos.  A common SNP in ER aminopeptidase 2 induces a specificity switch that leads to altered antigen processing. 2012 :J. Immunology: 189(5):2383-92. PMID: 22837489.
  91. Michael A. Morse, Elizabeth S. Gabitzsch, Amy C. Hobeika, Arvind Chaudhry, Takuya Osada, Timothy M. Clay, Andrea Amalfitano, Bruce K. Burnett, Gayathri R. Devi, David S. Hsu, Younong Xu, Rajesh Dua, Susan Nguyen, Stephanie Balcaitis, Joseph P. Balint, Jr, Frank R. Jones, and H. Kim Lyerly.  Novel Adenoviral Vector Induces T Cell Responses Despite Anti-Adenoviral Neutralizing Antibodies in Colorectal Cancer Patients. Cancer Immunol Immunother. 2013 Aug;62(8):1293-301.PMID:  23624851
  92. Charles F. Aylsworth, Yasser A. Aldhamen, Sergey S. Seregin, Sarah Godbehere, and Andrea Amalfitano.  Activation of Human Natural Killer Cells by the Novel Innate Immune Modulator Recombinant Eimeria Antigen. Human Immunology: 2013 Aug;74(8):916-26. PMID:23639554
  93. Yasser A. Aldhamen,, Sergey S. Seregin, David P.W. Rastall, Charles F. Aylsworth, Yuliya Pepelyayeva, Christopher J. Busuito, Sarah Godbehere-Roosa, Sungjin Kim, and Andrea Amalfitano.   Endoplasmic reticulum aminopeptidase-1 functions regulate key aspects of the innate immune response. PLoS One. 2013 Jul 24;8(7):e69539; PMID:23894499
  94. Sergey S. Seregin, David P.W. Rastall, Irini Evnouchidou, Charles F. Aylsworth, Dionisia Quiroga, Ram P. Kamal, Sarah Godbehere-Roosa, Christopher F. Blum, Ian A. York, Efstratios Stratikos, and Andrea Amalfitano.  Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens. Autoimmunity.. 2013 Dec;46(8):497-508. PMID:24028501
  95. YA Aldhamen, SS Seregin, YA Kousa, DPW Rastall, DM Appledorn, S Godbehere, BC Schutte and A Amalfitano.  Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2.  Cancer Gene Therapy, 2013 Oct;20(10):564-75. PMID:23949283
  96. Kovalenko PL, Yuan L, Sun K, Kunovska L, Seregin S, Amalfitano A, Basson MD.  Regulation of epithelial differentiation in rat intestine by intraluminal delivery of an adenoviral vector or silencing RNA coding for schlafen 3. PLoS One. 2013 Nov 11;8(11):e79745; PMID:24244554
  97. Efthalia Zervoudi, Emmanuel Saridakis, James R. Birtley, Sergey S. Seregin, Emma Reeves, Paraskevi Kokkala, Yasser A. Aldhamen, Andrea Amalfitano, Irene M. Mavridis, Edward James, Dimitris Georgiadis , and Efstratios Stratikos. Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses. PNAS,2013 Dec 3;110(49):19890-5; PMID:24248368
  98. Yasser A. Aldhamen, Sergey S. Seregin, Charles F. Aylsworth, Sarah Godbehere, and Andrea Amalfitano.  Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategy. International Immunology, 2014 , 26(5):291-303; PMID: 24374770 PMCID:  PMC4055832

Invited Manuscripts/Reviews:

  1. A. Amalfitano.  Genetic Implications of Newborn Screening. eJournal of the American College of Osteopathic Pediatricians. Subspecialty Review Section. Vol. 3 (2). 2011

Book Chapters:

  1. A. Amalfitano, J.A. Rafael, and J.S. Chamberlain. Structure and mutation of the dystrophin gene. Chapter 1 in:  Dystrophin: Gene, protein, and cell biology.. Editors:  S.C. Brown, J.A. Lucy 1997.
  2. A. Amalfitano. In vivo gene targeting of neuronal cells. Chapter 13 in: Apoptosis in Neurobiology.  CRC Methods in Neuroscience series. Editors: Hannun and Boustany, CRC Press, Boca Raton, Fl. 1998.
  3. A. Amalfitano.  Production of multiply deleted, helper virus independent Adenovirus vectors, Chapter 6 in: Viral vectors: Basic Science and Gene Therapy.  Biotechniques Books.  Editors A. Cid-Arregui and A Garcia-Carranca, 2000.
  4. Z. Hartman and A. Amalfitano.  Utility of Adenovirus-Based  Vectors, Chapter 14 in : Handbook of Cancer Vaccines, Of the Series: Cancer Drug Discovery and Development. Editors: M. Morse, T. Clay, and H.K. Lyerly, Humana Press, Totowa, NJ. 2004.
  5. A. Amalfitano.  Utilization of Adenovirus vectors for multiple gene transfer applications., Chapter 13 in :  Modern Mammalian Cell Transduction Techniques.  Of the series “Methods” Editor: A. Peel. 2004. Academic Press, Editors: A. Peel. Methods. 2004 Jun;33(2):173-8.
  6. Xu F., Serra D.,  and Amalfitano A. Applications of Adenoviral Vector-Mediated Gene Transfer in Cardiovascular Research. Methods Mol.Med 2006: 129:209-239.
  7. Appledorn, D., Seregin, S., and Amalfitano, A.  Adenovirus vectors for Renal Targeted Gene Therapy.   in Contributions to Nephrology (159) :Gene Therapy for Renal Diseases and Transplantation. Eds: A. Benigni and G. Remuzzi.2008.

Selected abstracts:

  1. J.S. Chamberlain, M.A. Hauser, J.A. Rafeal, K. Corrado, A. Amalfitano, R. Kumar-Singh.  Targeted delivery and expression of dystrophin minigenes to muscle.  The 77th Annual Meeting of the Endocrine Society, June 14-17, 1995, Washington, DC.  Abstract Book, p.2.
  2. J.S. Chamberlain, M.A. Hauser, J.A. Rafael, K. Corrado, A. Amalfitano, R. Kumar-Singh. Structure/function studies of dystrophin:  Functional analysis of mini-dystrophin genes.  Cell Bioc., 1995; 19C(S):362.
  3. A. Amalfitano, C.A. Begy, M.A. Hauser, R. Kumar-Singh, and J.S. Chamberlain.  Modification of adenoviral vectors for use in gene therapy of Duchenne muscular dystrophy.  Presented at the 45th Annual meeting of the American Society for Human Genetics, Symposium- Gene therapy, how and when?  Oct 26, 1995, Minneapolis, MN. Am J. Human Genetics 1995 57(4) Supplement. pA234.
  4. J.S. Chamberlain and A. Amalfitano.  Packaging cells expressing the Adenovirus (Ad) E1, polymerase, and preterminal proteins to allow the growth of a new class of replication defective Ad-vector for use in Duchenne muscular dystrophy (DMD).  Am J. Human genetics 1996; 59(4) Supplement. pA377.
  5. R. Kumar-Singh, D. Hartigan, M.A. Hauser, A. Amalfitano, and J.S. Chamberlain.  Encapsidated adenovirus minichromosomes as gene-delivery vehicles. Presented at the 46th Annual meeting of the American Society for Human Genetics, Poster Session, Nov 1, 1996. Am J. Human Genetics 1996; 59(4) Supplement. pA202.
  6. A. Amalfitano, and J.S. Chamberlain.  The utilization of  dystrophin-inducible mdx mice as a tool to assess the potential of gene therapy for Duchenne muscular dystrophy and other muscle diseases. Presented at the 46th Annual meeting of the American Society for Human Genetics, Symposium: “Mouse models of human disease and development”, Oct 31, 1996. Am J. Human Genetics 1996; 59(4) Supplement. pA195.
  7. J.S. Chamberlain, M.A. Hauser, D. Calnek, C. Barjot, R. Kumar-Singh, and A. Amalfitano. Gutted adenoviral vectors for gene therapy of Duchenne muscular dystrophy.  Keystone Symposia on the Molecular and Cellular Biology of Gene Therapy.  Snowbird, Utah, April 1997.
  8. A. Amalfitano, M.A. Hauser, and J.S. Chamberlain. A new class of adenovirus vector: the [E1-,E2b-]Ad vector.  Keystone Symposia on the Molecular and Cellular Biology of Gene Therapy.  Snowbird, Utah, April 1997.
  9. A. Amalfitano, D. Serra, M.A. Hauser, J. S. Chamberlain, and H. Hu.    In vivo effectiveness of improved adenovirus vectors.  Molecular and Cellular Biology of Gene Therapy, Keystone CO. Jan 19-25, 1998.
  10. J.Z. Baffi, A. Amalfitano, and KG Csaky. Evaluation of second generation adenoviral vectors for gene delivery into retinal pigment epithelial cells.  Assoc. for Research in Vision and Ophthalmology, May, 1998
  11. D. Hartigan-O’Connor, G. Salvatori, A. Amalfitano, and J.S. Chamberlain. Increased Efficiency of gutted adenovirus production in cells expressing preterminal protein and DNA polymerase.  1st annual meeting of the American Society of Gene Therapy, Seattle, WA. May 28-31, 1998.
  12. A. Amalfitano, D. Serra, and H. Hu.  Extended persistence and prolonged expression of highly immunogenic transgenes in immune-competnet animals via utilization of a unique class of adenovirus vector.  1st annual meeting of the American Society of Gene Therapy, Seattle, WA. May 28-31, 1998.
  13. A. Amalfitano, D. Serra, MA Hauser, JS Chamberlain, and H. Hu.  In vivo effectiveness of improved adenovirus vectors.  Molecular and Cellular Biology of Gene Therapy, Keystone, CO., Jan. 1998. 
  14. Kishnani P, Ahmad A, Amalfitano A, Chen Y-T. Dubowitz syndrome: A defect in the cholesterol biosynthetic pathway? Poster Presentation at the 47th American Society of Human Genetics, Denver, CO.  October 1998.
  15. A. Amalfitano, H. Hu., A.J. McVie, T.L. Dawson, M. Pennybacker, N. Raben, P. H. Plotz, and Y.T Chen.  A potential paradigm for the treatment of lysosomal disorders via modified adenovirus mediated gene therapy.  American Society for Human Genetics, Oct 1998. Am J. of Human Genetics 1998: 63(4) Supplement p. A397.
  16. A. Ahmad, M. Brinson, B. Hodges, J. Chamberlain, and A. Amalfitano.  American Somatic down-regulation of dystrophin expression suggests that dystrophin is stable for extended periods in vivo.  Society for Human Genetics, Oct 1998. Am J. of Human Genetics 1998: 63(4) Supplement p. A397.
  17. Bradley Hodges, Huimin Hu, Delila Serra, and Andrea Amalfitano. 2nd Expanding the Scope of the “TWO-HIT” hypothesis: Influence of tissue type, host Strain, and Additional Vector Modifications upon the Extended persistence of [E1-,E2b-] Adenovirus vectors encoding foreign genes.  Annual Meeting of the American Society of Gene Therapy, June 1999.
  18. A. Amalfitano, H. Hu, A.J. McVie, T.L. Dawson, N. Raben, P. Plotz, and Y.T. Chen.  The simultaneous correction of multiple muscle groups after a single intravenous administration of a modified adenovirus vector. 2nd Annual Meeting of the American Society of Gene Therapy, June 1999.
  19. B.L. Hodges, H. K. Evans, D. Serra, and A. Amalfitano. Efficient, High Level Production of Adenovirus vectors Deleted for Both E1 and 100K. 3rd Annual Meeting of the American Society of Gene Therapy, May 2000.
  20. B.L.Hodges, D.Serra, and A.Amalfitano. [E1-,E2b-] Adenovirus Vectors Persistently Express Foreign Genes in the Skeletal Muscles of Non-tolerant Mice Without the use of Immune-suppression.  3rd Annual Meeting of the American Society of Gene Therapy, May 2000.
  21. E. Ding, B.L. Hodges, A.J. McVie-Wylie, D. Serra, D. Koeberl, Y.T. Chen, and A. Amalfitano. Long Term Efficacy of [E1-,E2b-] Adenovirus Vector Mediated Gene Therapy for a Lysosomal Storage Disorder (Pompe disease) 3rd Annual Meeting of the American Society of Gene Therapy, May 2000.
  22. AE Luebke, JD Stieger, BL Hodges, A Amalfitano.  Cochlear Function During [E1-] and  [E1-, E2b-] Adenovirus Transduction of Guinea Pig Hair Cells.  University of Miami School of Medicine, Miami, FL  33136 and Duke University Medical Center, Durham, NC  27710. 3rd Annual Meeting of the American Society of Gene Therapy, May 2000.
  23. A. Lubke, J. Steiger, B. Hodges, A. Amalfitano.  A modified adenovirus can transfect coclear hair cells in vivo without compromising cochlear function.  ARO Mid-Winter Meeting, Miami, FL, Feb 2001.
  24. J.D. Harris, I.R. Graham, T. Athanasopoulos, S. Schepelmann, A.K. Stannard, B.L. Hodges, A. Amalfitano, D.G. Hassall, J.S. Owen, J.G. Dickson.  Atheroprotective effects of Apolipoprotein E (ApoE) gene transfer to ApoE-deficient mice using recombinant adeno-associated virus and adenovirus (E1, E2b and E3 deleted) vectors.  4th Annual Meeting of the American Society of Gene Therapy, Seattle, WA, May 30-June 3, 2001
  25. J.R. Holt, A. Amalfitano, A.E. Luebke.  In Vivo and In Vitro Expression of Transgenes in Mammalian Vestibular Hair Cells Infected with [E1-], and [E1-, E2b-] Adenoviral Vectors.  4th Annual Meeting of the American Society of Gene Therapy, Seattle, WA, May 30-June 3, 2001.
  26. A.E. Luebke, J.D. Steiger, R.J. Parks, A. AmalfitanoIn Vivo Adenovirus-Directed Gene Transfer to the Inner Ear:  1st, 2nd, and 3rd Generation Adenoviral Vectors.  Molecular Biology of Hearing and Deafness, Bethesda, MD, October 4-7, 2001.
  27. Bulsara, K.R., M.B. Ficklin, M. Lu, A. Amalfitano and J.H.P. Skene. 2001. Adenovirus vectors for retrograde delivery and sustained expression of neuronal growth-associated genes after spinal cord injury.  Soc.Neuroscience abstr. 257.18.
  28. Kishnani P, Voit T, Nicolino M, Amalfitano A, Straub V, Klinge L, Tixier F, Braakman T, Cox GF, and Chen YT.The safety and efficacy of recombinant human acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease:  Preliminary three month data from a Phase II study.  Platform presentation, Annual American College of Medical Genetics meeting in New Orleans, LA, March 2002. 
  29. Kishnani P, Voit T, Nicolino M, Amalfitano A, Straub V, Klinge L, Tixier F, Braakman T, Cox GF, and Chen YT.The safety and efficacy of recombinant human acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease:  Preliminary three month data from a Phase II study.  Platform presentation at the Annual SIMD meeting in Pacific Grove, CA. March 2002.
  30. Sun BD, Amalfitano A, Chen Y-T, Bird A, Hou YX, and Koeberl DD.  A modified hybrid adeno-associated virus-adenovirus vector encoding human acid-a-glucosidase (hGAA) for gene therapy in glycogen storage disease, type II (GSD II).  5th Annual Meeting, American Society of Gene Therapy, June 4-9, 2002, Boston, Massachusetts.
  31. E. Ding, H. Hu, B. L. Hodges, F. Migone, D. M. Serra, F. Xu, Y. T. Chen, and A. Amalfitano. Efficacy of Gene Therapy for a Prototypical Lysosomal Storage Disease (GSD-II) is Critically Dependent Upon Vector Dose, Transgene Promoter, and the Tissues Targeted for Vector Transduction. 5th Annual ASGT meeting, Boston MA, June 2002.
  32. HW Li, JZ Li, A. Amalfitano, GR Hankins, GA Helm. Construction of [E1-,E2b-] Adenoviral vectors with Human Bone Morphogenetic Protein -4 and -6 and  Their Ability to Induce Ectopic Bone Formation in Rats.. 5th Annual ASGT meeting, Boston MA, June 2002.
  33. Everett, R.E., Ding, E., Serra, D, and Amalfitano. Equivalent persistence of [E1-, E2b-] Ad vectors in diverse immunocompetent strains of mice accompanied by toxicity levels no different than those previously observed with use of “gutted” Ad vectors. 5th Annual ASGT meeting, Boston MA, June 2002.
  34. Kishnani P, Amalfitano A, Bengur A, Morse R, Majure J, Case L, Veerling D, Mackey J, Smith W, McVie-Wylie A, Sullivan J, Hoganson G, Phillips J, Schafer G, Charrow J, Ware R, Bossen E, and Chen Y-T.  Recombinant human acid a-glucosidase enzyme therapy for infantile glycogen storage disease type II:  Results of a phase I/II clinical trial, American College of Medical Genetics Meeting, Miami, FL.  Oral Presentation by March 2001.
  35. Kishnani P, Voit T, Nicolino M, Amalfitano A, Straub V, Klinge L, Tixier F, Braakman T, Cox GF, and Chen, YT.   Safety and efficacy of recombinant human acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease:  Preliminary three month data from a Phase II study.  Platform presentation at the Annual SIMD meeting in Pacific Grove, California.  March 2002.
  36. Kishnani P, Voit T, Nicolino M, Amalfitano A, Straub V, Klinge L, Tixier F, Braakman T, Cox GF, and Chen, YT.   Safety and efficacy of recombinant human acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease:  Preliminary three month data from a Phase II study.  Platform presentation in Biochemical/Molecular Genetics at the Annual American College of Medical Genetics, Clinical Genetics meeting in New Orleans, LA.  March 2002.
  37. Levine J, Colan S, Kishnani P, Amalfitano A, Tsai CH, Herman G, Waterson J, Rogers RC, Yong F,Chen YT. Administration of Recombinant Human Acid Alpha Glucosidase (rhGAA) to Patients with Infantile Pompe Disease Results in a Rapid Decrease in Left Ventricular Hypertrophy (LVH):  Preliminary Results from a Phase 2 Study. Am. Heart Assoc. 2002.
  38. Kishnani, P; Voit, T; Nicolino, M; Amalfitano, A; Tsai, C H; Herman, G; Waterson, J; Rogers, A7; Landy, H ; Cox, G ; Braakman, T ; Corzo, D ; Thurberg, B ; Richards, S ; Chen, Y T 1 RECOMBINANT HUMAN ACID ALPHA GLUCOSIDASE (rhGAA) FOR TREATMENT OF CLASSICAL INFANTILE POMPE DISEASE (CIPD): PRELIMINARY DATA FROM A PHASE 2 STUDY. Journal of Inherited Metabolic Disease. 25 Supplement 1:117, July 2002.
  39. Robert J. Kaner, Franck Rahaghi, Dmitri Igonkin, Andrea Amalfitano, Robin B. Parks, Shawn Kuhmann, John P. Moore, Ronald G. Crystal.  Ad E2b, in Part, Mediates Inhibition of HIV-1 Replication in Human Monocytic Cells.  6th Annual ASGT meeting, Washington, D.C. 2003.
  40. Xu, F. Ding, E., Migone, F., Serra, D., Schneider, A, Chen Y.T., and Amalfitano, A. Development of a new, immune-deficient, GSD-II mouse model confirms that anti-GAA antibody can limit the efficacy of gene therapy for GSD-II.   6th Annual ASGT meeting, Washington D.C. 2003.
  41. Xu, F. Ding, E., Migone, F., Serra, D., Schneider, A, Chen Y.T., and Amalfitano, A. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intra-venous injection with a modified adenoviral vector expressing hGAA.  6th Annual ASGT meeting, Washington D.C. 2003.
  42. Eric Weaver, Zhongjing Lu, Yingying Li, Larry Liao, Benjiang Ma, Munir Alam, Richard Scearce, Laura Sutherland, Julie Decker, Zachary Hartman, Andrea Amalfitano, Bette Korber, Beatrice Hahn, David Montefiori, Barton Haynes, and Feng Gao. Immunogenicity of HIV-1 Group M Consensus Env Immunogens.  AIDS Vaccine Meetings: New York, NY. Sep 18-21, 2003.
  43. J D Harris, I R Graham, S Schepelmann, A K Stannard, A Amalfitano3, D G Hassall, J S Owen, G Dickson. Protection against Atherosclerosis Utilising [E1, E2b and E3 deleted] Adenovirus Vectors containing Cellular and Liver-Specific Promoters Driving Expression of Human Apolipoprotein E (apoE) for Liver-Directed Gene Transfer in the apoE-/- Mouse.     European Society of Gene Therapy , 11th Annual Congress, Edinburgh UK, Nov. 2003.
  44. H. Jiang, R.Everett, Z. Wang, D.Serra, M.M. .Frank,  A.Amalfitano.  Recombinant Adenovirus vectors can bind the human complement protein C3 independent of anti-Ad antibodies, and subsequently activate the alternative complement pathway.  Oral presentation: European Society of Gene Therapy , 11th Annual Congress, Edinburgh UK, Nov. 2003.
  45. E.A. Weaver, Z. Lu, Y. Li, H-X. Liao, B. Ma, M.S. Alam, R.M. Scearce, L. Sutherland, J.M. Decker, Z. Hartman, A. Amalfitano, G. M. Shaw, B.T. Korber, B.H. Hahn, D.C. Montefiori, B.F. Haynes, F. Gao.  Cross-subtype Immune Responses of HIV-1 Group M Consensus Env Immunogens. 11th Annual Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11, 2004.
  46. Xiao Yi Yang, Takuya Osada, Bolyn Fralish, Christina Venturi, Donna Niedzwiecki, Michael A. Morse, Andrea Amalfitano, Jonathan Smith, H. Kim Lyerly, & Timothy M. Clay. A novel alphavirus vector expressing CEA breaks immunologic tolerance in mice transgenic for human CEA.  AACR Annual meeting, Orlando, FL. Mar. 2004.
  47. Takuya Osada, Xiao Yi Yang, Christina Bourgeois Venturi, Zachary Hartman, Delila Serra, Donna Niedzwiecki, Michael A. Morse, H. Kim Lyerly, Andrea Amalfitano, & Timothy M. Clay.  A novel non-replicating adenoviral vector expressing carcinoembryonic antigen (CEA) breaks tolerance to CEA in CEA-transgenic mice. AACR Annual meeting, Orlando, FL. Mar. 2004.
  48. Baodong Sun, Haoyue Zhang, Ayn Schneider, Andrew Bird, Andrea Amalfitano, Y.-T. Chen, and Dwight D. Koeberl. Correction of Glycogen Storage Disease Type II (GSD II) with an Adeno-Associated Virus 8 (AAV2/8) Vector.  7th Annual Meeting, American Association of Gene Therapy, June 2-5, 2004, Minneapolis, MN .
  49. Luis Franco, Baodong Sun, Andrew Bird, Haoyue Zhang, Andrea Amalfitano, Y.-T. Chen, and Dwight D. Koeberl. Sustained, High-level Expression of Human Acid Alpha-Glucosidase and Correction of Glycogen Storage Disease Type II (GSD II) with an Adeno-Associated Virus 8 (AAV2/8) Vector Containing a Liver-specific Promoter.  7th Annual Meeting, American Association of Gene Therapy, June 2-5, 2004, Minneapolis, MN.
  50. Robert J. Kaner, Francisco Santiago, Dmitri Igonkin, Jerome Schaack, Andrea Amalfitano, Ronald G. Crystal. Ad DNA Polymerase and Preterminal Protein (pTP) Genes Each Mediate Inhibition of HIV-1 Replication in Human Alveolar Macrophages.  7th Annual Meeting, American Association of Gene Therapy, June 2-5, 2004, Minneapolis, MN.
  51. H. Jiang, R.Everett, A. Kiang, Z. Wang, H. Zhang, D.Serra,  M.M. Frank, and A.Amalfitano.  Ad interactions with the complement systems of humans and mice.  7th Annual Meeting, American Association of Gene Therapy, June 2-5, 2004, Minneapolis, MN.
  52. Shaoxi Liao, R. Everett, F. Xu, D. Serra, N. Van Rooijen, Andrea Amalfitano Improved Efficacy of Adenovirus-Mediated Gene Therapy For GSD-II Disease by Selective Depletion of Kupffer cells.  . 7th Annual Meeting, American Association of Gene Therapy, June 2-5, 2004, Minneapolis, MN.
  53. A.Kiang, F.Xu, S. Liao,  D. Serra, D.J.Palmer, P. Ng, A Amalfitano. Unique potential of gene therapy for GSD-II using fully deleted adenovirus based vectors expressing hGAA.  7th Annual Meeting, American Association of Gene Therapy, June 2-5, 2004, Minneapolis, MN.
  54. A. Kiang1, Z. Hartman1, J. Wei1, D. Serra1, H. Jiang2, M.M. Frank2, A. Amalfitano1.  Evasion of the Innate Immune Response in Adenovirus Infused Complement C3 Deficient Mice. 8th Annual Meeting, American Association of Gene Therapy, 2005, St. Louis, MO. A. Kiang: Winner, Young Investigator Award.
  55. Z. Hartman, A. Kiang, R. Everett, E. Black, J. Nevins and A. Amalfitano.  Novel in vitro and in vivo transcriptome analysis identifies new Adenovirus  responsive, innate gene networks. 8th Annual Meeting, American Association of Gene Therapy, 2005, St. Louis, MO.
  56. Xu, F, Serra, D, A.Amalfitano.  A novel replication competent, but packaging deficient adenoviral (Ad) vector [E1+, 100K-] for high level hGAA expression and reduced toxicity in gene therapy of Glycogen Storage Disease II (GSD-II). 8th Annual Meeting, American Association of Gene Therapy, 2005, St. Louis, MO. F. Xu: Winner, travel award.
  57. In vivo, High Throughput analysis expands the known anti-Ad innate immune response profile, and implicates TLR pathways in Ad cellular immune response. 9th Annual Meeting, American Society of Gene Therapy, 2006, Baltimore, MD.
  58. A new, plasmid-based adenoviral vectoring system derived from the highly immunogenic, human Ad4 strain. Hartman Z.C., Mendelson T., and Amalfitano, A.9th Annual Meeting, American Society of Gene Therapy, 2006, Baltimore, MD.
  59. Decreased DHA in diabetic retina is caused by reduction in retinal specific elongase, Elovl-4.  Maria Tikhonenko, Sergey Seregin, Andrea Amalfitano and Julia Busik. American Diabetes Association: 67th Annual Scientific Sessions; June 22-26, 2007.
  60. Identification of TLR2 as a mediator of the innate immune response to adenoviral vectors.Appledorn, DM; Scott, JS; Amalfitano 10th Annual Meeting of the American Association of Gene Therapy.2007
  61. TLR4 and TRIF play both positive and negative roles in Ad induced innate immunity in vivo.  Appledorn, DM; Hartman, ZC; Scott, JS; Amalfitano, A.10th Annual Meeting of the American Association of Gene Therapy.2007.
  62. Characterization of Adenovirus Serotypes Representative of Groups A-E. Appledorn, DM; Scott, JS; Kiang, A.; Amalfitano, A  10th Annual Meeting of the American Association of Gene Therapy.2007. (Selected for oral Presentation.).
  63. Adenovirus Induced Innate Immune Responses are Mediated in Part by the Presence of Natural Antibodies in Ad naive Mice.  Jeannine M. Scott, PhD1, Tyler T. Voss, BS1, Daniel M. Appledorn, PhD1 and Andrea Amalfitano, DO, PhD1,2. 10th Annual Meeting of the American Association of Gene Therapy.2007.
  64. Adenovirus vector induced immune responses are dependent upon muti-faceted interactions with proteins of both the alternative and classical complement pathways in vivo.  Scott, JS., Kiang,A., Appledorn, D, McBride, A.,Amalfitano, A. 10th Annual Meeting of the American Association of Gene Therapy.2007. (Selected for oral presentation).
  65. Campylobacter jejuni-induced Activation of Murine Dendritic Cells Involves Cooperative Signaling through MyD88 and TRIF. Vijay A.K. Rathinam, Daniel M. Appledorn, Jennifer D. Olmstead, Kathleen A. Hoag, Andrea Amalfitano and Linda S. Mansfield. Annual American Society of Microbiology Meeting Boston, MA. 2008
  66. Transient pre-treatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.  ASGT 12-th annual Meeting, May 27 – May 30, 2009, San Diego, CA, USA: 639
  67. Complement receptors regulate several aspects of Adenovirus (Ad) vector induced innate and adaptive immune responses in vivo. Seregin, S.S., Y.A. Aldhamen, D.M. Appledorn, N.J. Schuldt, A.J. McBride, M. Bujold, S.S. Godbehere, and A. Amalfitan. May 27 – May 30, 2009. American Society of Gene Therapy (ASGT) 12-th annual Meeting (San Diego, CA), 957.
  68. Improved safety profile of novel Adenovirus based vectors “capsid-displaying” complement inhibitors: increased potential for cardiovascular gene transfer applications. Sergey Seregin, Y. A. Aldhamen, D. M. Appledorn, Z. C. Hartman, N. J. Schuldt, J. Scott, S. Godbehere, H. Jiang, M. M. Frank, and A. Amalfitano.  American Heart Association Scientific Sessions, November 14 – 18, 2009, Orlando, FL, USA (Oral Presentation).
  69. Incorporation of Immunostimulatory TLR Agonists into Virus Based Vaccine Platforms Improves Immune Responses to Antigenic Targets.  D. M. Appledorn, Y. A. Aldhamen, W. DePas, S. S. Seregin, C. Liu, N. Schuldt,           D. Quach, D. Quiroga, S. Godbehere, I. Zlatkin, S. Kim, J. McCormick, A. Amalfitano. Oral Presentation.13th Annual Congress on Vaccine Research, April 26-28th, Bethesda, MD.
  70. Novel Class of Adenovirus Vector Capsid−Displaying the Retro−Oriented Human Complement Inhibitor DAF Has a Significantly Improved Safety Profile In Vivo. Seregin, S.S., Y.A. Aldhamen, D.M. Appledorn, Z.C. Hartman, N.J. Schuldt, J.M. Scott, S. Godbehere, H. Jiang, M.M. Frank, and A. Amalfitano. 2010. American Society of Gene and Cell Therapy (ASGCT) 13-th annual Meeting (Washington, DC) 638.
  71. Overexpression of EAT-2, a novel immunostimulatory modulator, prevents upregulation in APCs in a PLCγ and MAPK/ERK dependent mechanism in vivo. Aldhamen Y.A., Sergey S.  Seregin, Chyong-jy J. Liu, Charles F. Aylsworth, Sarah Godbehere, Andrea AmalfitanoThe American Association of Immunologists  (AAI) 98th annual Meeting, May 13-17, 2011 (San  Francisco, CA).
  72. The vaccine Ad5 [E1-, E2b-]-CEA(6D) induces CEA-directed CMI responses despite neutralizing anti-Ad immunity in patients with advanced CEA-expressing malignancies in a phase I/II clinical trial. Michael Morse, Amy Hobeika, Arvind Chaudhry, Andrea Amalfitano, Donna Niedzwiecki, Timothy M. Clay, Takuya Osada, Gayathri Devi, Bruce K. Burnett, Kent Weinhold, Shiaowen David Hsu, Gerard C. Blobe, Younong Xu, Susan Nguyen, Rajesh Dua, Stephanie Balcaitis, Elizabeth Gabitzsch, Joseph Balint Jr., Frank Jones, H. Kim Lyerly. American Society of Clinica Oncology Annual meeting June1-5, 2012 (Chicago, IL).
  73. Despite Pre-existing Ad5 Immunity, Recombinant Adenovirus Vectors Expressing the Innate Immune Modulator EAT-2 Elicits Potent Effector Memory T Lymphocyte Responses. Aldhamen Y.A., Sergey S. Seregin, Nathaniel J. Schuldt, David P.W. Rastall, Sarah Godbehere, Andrea Amalfitano1,2*.15th Annual Conference on Vaccine Research. National Foundation for Infectious Diseases, May 7-9, 2012 Bethesda, MD, USA S24. (Oral Presentation)
  74. Extracellular ERAP1 activates innate cytokine production and downstream effector functions via the NALP3 inflammasome and TLR-9 pathways.  Yasser A. Aldhamen1, Yuliya Pepelyayeva1, David P.W. Rastall1, Sergey S.  Seregin1, Efthalia Zervoudi3, Despina Koumantou3, Charles F. Aylsworth1, Sarah Godbehere1, Dimitris Georgiadis4, Efstratios Stratikos3, Andrea Amalfitano1,2* , 9th International Congress on Autoimmunity, Session: PS56 -Cytokines & Autoimmunity, March 26-30, 2014 Nice, France. (Accepted for Oral Presentation)
  75. Enhanced Cancer Immunotherapy Using Vaccines Expressing the Innate Immune Modulator EAT2 and Carcinoembryonic Antigen. Aldhamen Y.A., Sergey S.  Seregin1, Youssef A. Kousa3, David P.W. Rastall1, Daniel M. Appledorn1, Sarah Godbehere1, Brian C. Schutte1,2,3, Andrea Amalfitano1,2* Great Lakes International Imaging and Flow Cytometry Association (GLIIFCA)  2013 (YA: Invited Speaker, Young Investigator Award) September 27-29, 2013 Detroit, MI, USA

 

Andrea Amalfitano

Professor

 

  • : 1-517-884-5324
  • : 1-517-353-8957

  • DEPARTMENTDepartment of Microbiology and Molecular Genetics
    College of Osteopathic Medicine
    Michigan State University
  • COUNTRY USA